Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology  ( ASCO )  Annual Meeting - Allogene Therapeutics  ( NASDAQ:ALLO )